Cochrane · systematic review · CD006407
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia
Peinemann, F, Bartel, C, Grouven, U · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 4 · 57.1%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia
Population: patients with acquired SAA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | HR 0.95 [0.45, 1.91] | 3 studies · 203 participants | Low Downgraded: imprecision |
Treatment‐related mortality First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | no estimate extracted | 2 studies · 54 participants | Very low |
Health‐related quality of life First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | no estimate extracted | 0 studies · 0 participants | Ungraded |
Graft failure First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | no estimate extracted | 2 studies · 54 participants | Very low |
No response to IST First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | no estimate extracted | 2 studies · 35 participants | Very low |
Graft‐versus‐host disease First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | no estimate extracted | 2 studies · 52 participants | Very low |
Secondary clonal disease or malignancies First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin | Peto OR 0.54 [0.07, 4] | 2 studies · 170 participants | Low Downgraded: imprecision |